Escugen

Focus: Escugen is a Shanghai-based biotechnology company focused on antibody and antibody-drug conjugate (ADC) development targeting oncology and hematology indications.

Oncology Hematology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Escugen

AI assessmentNot Hiring

No open roles listed right now. Follow Escugen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ESG406

Locally Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT06979674Study of ESG406 in Adults With Solid Tumors

Phase 1

Help build intelligence for Escugen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with multiple shots on goal across oncology and immunology, including ESG206 in Phase 2 for Primary Sjögren Syndrome
Focused modality expertise in antibodies and ADCs positions you in high-value therapeutic area with sustained pharma investment
China-based headquarters offers access to growing biotech innovation hub with lower cost of development and proximity to large patient populations

Watch Out For

Zero active job postings indicate minimal near-term hiring and potentially constrained headcount
No public financial data, revenue, or funding information raises transparency and stability concerns for career planning

Generated by Claude from Escugen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ESG206

B-cell Lymphoid Malignancies

Phase 1

Clinical Trials (1)

NCT05263739A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Phase 1

ESG206

B-cell Lymphoid Malignancies

Phase 1

Clinical Trials (1)

NCT05822843A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Phase 1